AbbVie Inc. (NYSE:ABBV) is included among the The 13 Best Roth IRA Stocks to Buy Now. Evercore ISI cuts AbbVie Inc. (ABBV) PT, says consensus for 2026 and 2027 still looks beatable On February 5, Evercore ISI analyst Gavin Clark-Gartner cut his price recommendation for AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained…
AbbVie Inc. (NYSE:ABBV) is one of Best-Performing Pharma Stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer Perform from Outperform on January 8 by Wolfe Research without a price target. The company said the stock already reflects expectations of outperformance in Skyrizi and Rinvoq, so it is sitting on the sidelines pending greater visibility…
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for AbbVie to $269 from $261 with an Overweight rating on the stock. Early on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, up from…
